Olema Oncology, Inc., formerly Olema Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. It is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Its lead product candidate, palazestrant (OP-1250), is a proprietary, orally available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD). Palazestrant is also being evaluated in multiple Phase I/II studies in combination with ribociclib, palbociclib, alpelisib, everolimus and atirmociclib. The Company is developing OP-3136, a novel, orally available small molecule that potently and selectively inhibits lysine acetyltransferase 6 (KAT6), an epigenetic target that is dysregulated in breast and other cancers.
Company Information
About this company
Key people
Key facts
- Shares in issue87.61m
- EPICOLMA
- ISINUS68062P1066
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$618.50m
- Employees150
- ExchangeNASDAQ
- IndexTR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.